Close To Filing Esmya, PregLem Licenses Candidate For Post-Operative Adhesions
This article was originally published in The Pink Sheet Daily
Executive Summary
The Swiss women's reproductive health-focused firm plans to move new program into Phase II in 2011.
You may also be interested in...
VCs Back ObsEva With $35M For Trials On Pre-term Labor Drug
The Swiss start-up will conduct a Phase II study on a compound that may reduce or prevent pre-term labor contractions, licensed from Merck Serono. It hopes to follow in the footsteps of another women's health company, PregLem, which provided exceptional returns with the same CEO and similar investors.
PregLem Weighs Financing Options Well Ahead Of Uterine Fibroid Drug Launch
Esmya, an oral therapy being developed for symptomatic uterine fibroids, showed non-inferiority to GnRH agonists in a Phase III study.
Cancer-Genomics Firm Quanticel Debuts With Close Ties To Celgene, And An Exit In Mind
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.